GlassScriptPhysician profile
Arnett Carraby
NPI 1366530792
$4,883.12
in general payments reported to CMS, 2019-2025
22 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $471 · 2021: $509 · 2022: $694 · 2023: $1,026 · 2024: $1,257 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,772.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,837.11 | 2019-2025 | Argos, Clareon, Rocklatan |
| Bausch & Lomb Americas INC. | $467.97 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $416.14 | 2020-2025 | Cequa |
| Dompe US, INC. | $311.08 | 2022-2025 | Oxervate |
| Oyster Point Pharma, INC. | $264.89 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $203.88 | 2022-2025 | Lumigan, Alphagan P |
| Mallinckrodt Hospital Products INC. | $196.97 | 2021-2025 | Acthar |
| Glaukos Corporation | $185.33 | 2020-2023 | Photrexa Cross-Linking Kit |
| Ivantis, INC | $183.21 | 2020-2021 | |
| Horizon Therapeutics Plc | $165.36 | 2021-2023 | Tepezza |
| Sight Sciences, INC. | $109.60 | 2020-2021 | |
| Boston Scientific Corporation | $89.95 | 2024 | Wavewriter Alpha Prime 16 |
| Harrow Eye, LLC | $89.63 | 2024-2025 | Vevye |
| Ani Pharmaceuticals, INC. | $78.01 | 2024 | Purified Cortrophin Gel |
| Allergan, INC. | $75.52 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $61.82 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $52.29 | 2024-2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $28.41 | 2025 | Syfovre |
| Thea Pharma INC. | $21.11 | 2024 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $16.66 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.74 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnett Carraby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.